Literature DB >> 7851107

Simulation as a design tool for phase I/II clinical trials: an example from bone marrow transplantation.

T A Gooley1, P J Martin, L D Fisher, M Pettinger.   

Abstract

We discuss the design and analysis of a proposed phase I/II clinical trial in bone marrow transplantation whereby dose modifications that decrease the risk of one complication increase the risk of another. Trials of this type are carried out to determine whether a dose can be found that balances the risks of each complication. Three different scenarios describing potential relationships between each risk and the treatment dose are postulated. The scenarios encompass both favorable situations in which several acceptable doses exist and unfavorable situations in which no acceptable dose exists. The operating characteristics of three sequentially developed trial designs were examined by simulation under each dose-response scenario. The first design was derived from seemingly reasonable rules, but simulations showed that performance fell far short of what was desired, thus motivating modifications. Subsequent designs showed improved performance characteristics compared to the original design. Without close examination of the operating characteristics, the original design would have been implemented, leading to high risk of an erroneous conclusion.

Mesh:

Year:  1994        PMID: 7851107     DOI: 10.1016/0197-2456(94)90003-5

Source DB:  PubMed          Journal:  Control Clin Trials        ISSN: 0197-2456


  19 in total

1.  A robust Bayesian dose-finding design for phase I/II clinical trials.

Authors:  Suyu Liu; Valen E Johnson
Journal:  Biostatistics       Date:  2015-10-20       Impact factor: 5.899

2.  Adaptive clinical trial designs in oncology.

Authors:  Yong Zang; J Jack Lee
Journal:  Chin Clin Oncol       Date:  2014-12

3.  BAYESIAN PHASE I/II ADAPTIVELY RANDOMIZED ONCOLOGY TRIALS WITH COMBINED DRUGS.

Authors:  Ying Yuan; Guosheng Yin
Journal:  Ann Appl Stat       Date:  2011-01-01       Impact factor: 2.083

4.  A Bayesian dose-finding design for phase I/II clinical trials with nonignorable dropouts.

Authors:  Beibei Guo; Ying Yuan
Journal:  Stat Med       Date:  2015-01-28       Impact factor: 2.373

5.  One Size Fits All?: Ethical Considerations for Examining Efficacy in First-in-Human Pluripotent Stem Cell Studies.

Authors:  Michelle Gjl Habets; Johannes Jm van Delden; Sophie L Niemansburg; Harold L Atkins; Annelien L Bredenoord
Journal:  Mol Ther       Date:  2016-12       Impact factor: 11.454

6.  Seamless Phase IIa/IIb and enhanced dose-finding adaptive design.

Authors:  Jiacheng Yuan; Herbert Pang; Tiejun Tong; Dong Xi; Wenzhao Guo; Peter Mesenbrink
Journal:  J Biopharm Stat       Date:  2015-09-21       Impact factor: 1.051

7.  A Bayesian Phase I/II Trial Design for Immunotherapy.

Authors:  Suyu Liu; Beibei Guo; Ying Yuan
Journal:  J Am Stat Assoc       Date:  2018-06-28       Impact factor: 5.033

Review 8.  Adaptive designs for randomized trials in public health.

Authors:  C Hendricks Brown; Thomas R Ten Have; Booil Jo; Getachew Dagne; Peter A Wyman; Bengt Muthén; Robert D Gibbons
Journal:  Annu Rev Public Health       Date:  2009       Impact factor: 21.981

9.  A new approach to designing phase I-II cancer trials for cytotoxic chemotherapies.

Authors:  Jay Bartroff; Tze Leung Lai; Balasubramanian Narasimhan
Journal:  Stat Med       Date:  2014-02-27       Impact factor: 2.373

10.  Effective sample size for computing prior hyperparameters in Bayesian phase I-II dose-finding.

Authors:  Peter F Thall; Richard C Herrick; Hoang Q Nguyen; John J Venier; J Clift Norris
Journal:  Clin Trials       Date:  2014-09-01       Impact factor: 2.486

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.